SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) — CytomX Therapeutics (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results from its Probody therapeutics pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2016 from April 16-20 in New Orleans, Louisiana.
“The data being presented at this year’s AACR Annual Meeting represent the next wave of preclinical programs from our growing pipeline of Probody therapeutics for the treatment of cancer,” said Michael Kavanaugh, M.D., chief scientific officer of CytomX.
Abstracts to be Presented at AACR
Title: Development of a Probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas
- Tuesday Apr 19, 2016 8:00 a.m. – 12:00 p.m. CDT
- Halls G-J, Poster Section 15
- Abstract 2975
Title: PD-1-targeted Probody therapeutics provide anti-tumor efficacy and a 10-fold dose protection against systemic autoimmunity in preclinical studies
- Tuesday Apr 19, 2016 8:00 a.m. – 12:00 p.m. CDT
- Halls G-J, Poster Section 25
- Abstract 3211
Therapeutics developed with CytomX’s Probody platform are designed to be active in the tumor while sparing healthy tissue. Due to their specific activity in the tumor microenvironment, Probody therapeutics directed against both validated and novel targets enable anti-tumor efficacy with a significantly enhanced safety window, relative to traditional antibody-based therapies. CytomX’s preclinical pipeline of wholly-owned and partnered programs includes Probody cancer immunotherapies, Probody drug conjugates and T-cell engaging Probody bispecifics.
About CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CytomX believes that its Probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Investigational Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1 against which clinical candidate CX-072 is directed, as well as novel targets, such as CD-166, that are difficult to drug without causing damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc., The University of Texas MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com.
Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements. Our Probody platform is in preclinical development, and the process by which a preclinical technology could potentially lead to an approved product is long and subject to significant risks and uncertainties. Applicable risks and uncertainties include those relating to our preclinical research and development and other risks identified under the heading “Risk Factors” included in our filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
PROBODY is a trademark of CytomX Therapeutics, Inc.
CONTACT: Corporate Communications Contacts: Canale Communications Ian Stone ian@canalecomm.com 619-849-5388 Investor Contacts: Trout Group Pete Rahmer prahmer@troutgroup.com 646-378-2973
